YOUR GIFT WILL MAKE A DIFFERENCE
ASPI is a Place for Information and Answers for men with prostate cancer. Your gift will be used to build our vast resource Base of Information and expand our Base of Answers providing the knowledge you need when you need it the most.
ASPI uses the funding you provide to continuously explore the rapidly changing world of Prostate Cancer, seeking out the latest developments in diagnosis, technology, nutrition, exercise and treatments. All of which requires an investment in staff time and resources.
We provide you with information and answers on the latest developments in the form of our newsletter, blog posts, and webinars presented by experts in the field of prostate cancer. Knowledge equips you with information and answers that prepare you to intelligently discuss your diagnosis with medical professionals and your family. Knowledge is the Critical tool you need to make informed decisions as to how you will move forward and live your life.
PLEASE HELP US BY GIVING NOW TO ASPI
ASPI is a 501(c)(3) approved not-for-profit education and research organization that advances improved outcomes for prostate cancer patients. E.I.N 82-5386351.
Click on the links below to make your secure online one-time donation or recurring donation.
Or make your check payable to Active Surveillance Patients International and send to:
Mark Lichty, Chairman
188 Winchester Drive
E. Stroudsburg, PA 18301
If you have any questions, email mlichty@aspatients.org
And see below how you can help ASPI every time you shop at Amazon!
THANK YOU!
Testimonials
“Before we started Active Surveillance Patients International (ASPI), there was no support or educational programs for men on active surveillance by men on active surveillance. ASPI helps men with low- to low-intermediate-risk prostate cancer avoid or defer unnecessary radical treatments that can destroy men’s quality of life as well as avoid transrectal biopsies that can cause potentially disabling and deadly septic shock.”
– Howard Wolinsky, low-risk prostate cancer patient and co-founder of ASPI.
“The best of three presentations I have heard dealing with the emotional aspect of Active Surveillance. Well done.”
– Tony Henry, ASPI supporter, referring to our June 2021 webinar
“In spite of a rising PSA that peaked at 9.8, and results from a recent biopsy (my third in over 2.5 years) that indicated no cancer detected based on 12 samples, I am on Active Surveillance. To date, I have been following the AS protocol for nearly three years. I had read an article in the periodical MedPage by Howard Wolinsky which clicked with me. Couple this with credible sources being cited in the context of his research, one would be hard-pressed to effectively challenge the information and perspectives presented in this article. This is significant given my urologist’s repeated attempts to get me to trust him and AS protocols. In summary: Thank you, Mr. Wolinsky and ASPI! The members of ASPI are making a positive difference by publishing well-researched articles, organizing virtual seminars with credible, credentialed speakers on relevant topics, and by sharing their experience with others who unexpectedly find themselves as a member in the “reluctant brotherhood.”
– Anonymous
Our Sponsors
Informed Prostate Cancer Support Group
Because we offer the complete spectrum of information on prevention and treatment, we provide a forum where you can get all your questions answered in one place by men that have lived through the experience.
Myriad Genetics, Inc.
Myriad Genetics, Inc. is an American genetic testing and precision medicine company based in Salt Lake City, Utah, United States. Myriad employs a number of proprietary technologies that permit doctors and patients to understand the genetic basis of human disease and the role that genes play in the onset, progression and treatment of disease.
Other Ways to Donate
Support ASPI by shopping at Amazon
When you shop @AmazonSmile, Amazon will make a donation to Active Surveillance Patients International. Start your Amazon order by clicking the Amazon Smile icon below:
Checks
Thank you for your consideration. Please send your check to:
ASPI c/o Mark Lichty
188 Winchester Drive
E. Stroudsburg, PA 18301
If you have any questions, email mlichty@aspatients.org
Bequests, Wills & Living Trusts, Stocks & Investments
Thank you for your consideration. To learn how to maximize the value of your IRA please read the following document on Qualified Charitable Distributions by clicking the link.
For information on bequests, wills, and living trusts, please email us at mlichty@aspatients.org.
ASPI is a 501(c)(3) approved not-for-profit education and research organization that advances improved outcomes for prostate cancer patients. E.I.N 82-5386351.
We’re excited to share that our organization has earned a 2022 Gold Seal of Transparency with Candid! Now, you can support our work with trust and confidence.
Liberating Research pays ASPI for your medical survey participation.
Liberating Research, a London (UK) healthcare market research recruitment agency recruits patients and caregivers to share their valuable opinions through a variety of research methodologies to ensure your voices are heard (face to face, online, over the phone to name a few) whilst also fundraising for charities at the same time. It works by you going to their website: www.liberatingresearch.com, signing up (if you wish to participate and become a member) and when a survey or research activity becomes available that would be applicable to you, they will contact you to see if you’d be interested in taking part (you can decline or request to be removed as a panelist at any time). All market research interviews hold an incentive as a thank you for your contributions, and 10% of your earnings (or more if you wish) is also donated to a registered healthcare charity of your choosing (you can select ASPI as your preferred charity as we are now on their system under ‘Charities’). You can also find out additional information about how they protect your data in their privacy policy: www.liberatingresearch.com/privacy.